Xalkori 200 mg and 250 mg Capsules.
PDF Leaflet Revision Date: 15 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of ALK-positive or ROS1-positive advanced NSCLC in adults.
Dosage (summary)
250 mg orally twice daily; dose adjustments for tolerability.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; use contraception during treatment.
Key Drug Interactions
- Avoid strong CYP3A inhibitors (e.g., ketoconazole, grapefruit juice)
- Avoid strong CYP3A inducers (e.g., rifampicin, St. John's wort)
Contraindications
- Hypersensitivity to crizotinib or excipients
Common side effects
- Vision disorder
- Nausea
- Diarrhoea
- Vomiting
- Fatigue
- Bradycardia
Counselling Points
- Monitor for liver function and cardiac symptoms.
- Avoid grapefruit and St. John's wort.
- Report any vision changes immediately.
Serious warnings
- Hepatotoxicity
- Interstitial lung disease
- QT interval prolongation
- Cardiac failure
Important Disclaimer
The Xalkori 200 mg and 250 mg Capsules. professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
